Ryan Cassaday, MD
Hematology & Oncology · Seattle, WANPI 1508060583
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $108,892 of the $150,530 with a category attached, or 72.3%. 10 manufacturers reported payments, led by Gilead at 30.3% of the total. Reporting peaked in 2022 at $34,253 and has fallen 53.1% since, to $16,073 in 2025. Among hematology & oncology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 85 payments — averaging $1770.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$46K
- Pfizer$41K
- Amgen$36K
- Jazz Pharmaceuticals Inc.$8K
- Servier Pharmaceuticals LLC$7K
- Autolus Inc$5K
- plus $7K from 4 others
Across 261 payments — averaging $86,827 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$14.7M
- Pfizer$5.5M
- Servier Bioinnovation$1M
- Incyte Corporation$722K
- Gilead$222K
- Institut DE Recherches Servier$194K
- plus $284K from 3 others
What the payments were for
- Consulting fees$108,89272%
- Speaking & faculty fees$36,63024%
- Travel & lodging$3,8973%
- Food & beverage$1,1111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 18 | $45,671 |
| Pfizer | 24 | $41,286 |
| Amgen | 23 | $35,597 |
| Jazz Pharmaceuticals Inc. | 7 | $7,733 |
| Servier Pharmaceuticals LLC | 2 | $7,420 |
| Autolus Inc | 4 | $5,391 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $3,300 |
| Merck | 4 | $2,471 |
| AstraZeneca | 1 | $1,640 |
| Novartis | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$150,530 in reported general payments places this provider in the 95th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ursodiol | 12 | $705 |
| Acyclovir | 12 | $120 |
| Prednisone | 18 | $98 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Seattle
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Celestia HiganoSeattle$164K
- Rebecca Kruse-JarresSeattle$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.